Neural Tube Defects
|
0.320 |
GeneticVariation
|
group |
BEFREE |
We reviewed the literature for ZIC2-ZIC5 deletions and their involvement in neural tube defects (NTDs).
|
21496007 |
2012 |
Neural Tube Defects
|
0.320 |
Biomarker
|
group |
BEFREE |
Mouse Zic5 deficiency results in neural tube defects and hypoplasia of cephalic neural crest derivatives.
|
15136147 |
2004 |
Neural Tube Defects
|
0.320 |
Biomarker
|
group |
CTD_human |
Mouse Zic5 deficiency results in neural tube defects and hypoplasia of cephalic neural crest derivatives.
|
15136147 |
2004 |
Liver carcinoma
|
0.310 |
Biomarker
|
disease |
BEFREE |
Overall, this study reveals a novel mechanism of ZIC5/β-catenin that mediates the invasion and metastasis of HCC and ZIC5 serves as a novel indicator for prognosis of HCC patients.
|
30086882 |
2018 |
Liver carcinoma
|
0.310 |
Biomarker
|
disease |
CTD_human |
Computational Discovery of Niclosamide Ethanolamine, a Repurposed Drug Candidate That Reduces Growth of Hepatocellular Carcinoma Cells In Vitro and in Mice by Inhibiting Cell Division Cycle 37 Signaling.
|
28284560 |
2017 |
Diastematomyelia
|
0.300 |
Biomarker
|
disease |
CTD_human |
Mouse Zic5 deficiency results in neural tube defects and hypoplasia of cephalic neural crest derivatives.
|
15136147 |
2004 |
Neurenteric Cyst
|
0.300 |
Biomarker
|
disease |
CTD_human |
Mouse Zic5 deficiency results in neural tube defects and hypoplasia of cephalic neural crest derivatives.
|
15136147 |
2004 |
Tethered Cord Syndrome
|
0.300 |
Biomarker
|
disease |
CTD_human |
Mouse Zic5 deficiency results in neural tube defects and hypoplasia of cephalic neural crest derivatives.
|
15136147 |
2004 |
Iniencephaly
|
0.300 |
Biomarker
|
disease |
CTD_human |
Mouse Zic5 deficiency results in neural tube defects and hypoplasia of cephalic neural crest derivatives.
|
15136147 |
2004 |
Craniorachischisis
|
0.300 |
Biomarker
|
disease |
CTD_human |
Mouse Zic5 deficiency results in neural tube defects and hypoplasia of cephalic neural crest derivatives.
|
15136147 |
2004 |
Exencephaly
|
0.300 |
Biomarker
|
disease |
CTD_human |
Mouse Zic5 deficiency results in neural tube defects and hypoplasia of cephalic neural crest derivatives.
|
15136147 |
2004 |
Spinal Cord Myelodysplasia
|
0.300 |
Biomarker
|
disease |
CTD_human |
Mouse Zic5 deficiency results in neural tube defects and hypoplasia of cephalic neural crest derivatives.
|
15136147 |
2004 |
Craniofacial Abnormalities
|
0.300 |
Biomarker
|
group |
CTD_human |
Mouse Zic5 deficiency results in neural tube defects and hypoplasia of cephalic neural crest derivatives.
|
15136147 |
2004 |
Acrania
|
0.300 |
Biomarker
|
disease |
CTD_human |
Mouse Zic5 deficiency results in neural tube defects and hypoplasia of cephalic neural crest derivatives.
|
15136147 |
2004 |
Neoplasm Metastasis
|
0.030 |
AlteredExpression
|
phenotype |
BEFREE |
SNHG4 promoted ZIC5-mediated growth and metastasis through modulating miR-377.
|
31608997 |
2020 |
Malignant neoplasm of prostate
|
0.030 |
Biomarker
|
disease |
BEFREE |
In addition, miR-377 was a target of SNHG4 and ZIC5 was a target gene of miR-377 in PCa.
|
31608997 |
2020 |
Prostate carcinoma
|
0.030 |
Biomarker
|
disease |
BEFREE |
In addition, miR-377 was a target of SNHG4 and ZIC5 was a target gene of miR-377 in PCa.
|
31608997 |
2020 |
Neoplasm Metastasis
|
0.030 |
Biomarker
|
phenotype |
BEFREE |
Overall, this study reveals a novel mechanism of ZIC5/β-catenin that mediates the invasion and metastasis of HCC and ZIC5 serves as a novel indicator for prognosis of HCC patients.
|
30086882 |
2018 |
Neoplasm Metastasis
|
0.030 |
Biomarker
|
phenotype |
BEFREE |
ZIC5 enhanced melanoma cell proliferation, survival, drug resistance, in vivo growth and metastasis.
|
27671679 |
2017 |
Malignant neoplasm of prostate
|
0.030 |
AlteredExpression
|
disease |
BEFREE |
In addition, suppression of ZIC5 or PDGFD expression decreased levels of phosphorylated focal adhesion kinase (FAK) and signal transducer and activator of transcription 3 (STAT3) which are associated with PCa and CRC aggressiveness.
|
29024195 |
2017 |
Prostate carcinoma
|
0.030 |
AlteredExpression
|
disease |
BEFREE |
In addition, suppression of ZIC5 or PDGFD expression decreased levels of phosphorylated focal adhesion kinase (FAK) and signal transducer and activator of transcription 3 (STAT3) which are associated with PCa and CRC aggressiveness.
|
29024195 |
2017 |
Malignant neoplasm of prostate
|
0.030 |
Biomarker
|
disease |
BEFREE |
HELLS was independently predictive for biochemical-recurrence after radical prostatectomy (HR 2.3; CI 1.5-3.6; p < 0.01).In conclusion, HELLS and ZIC5 might be promising candidate markers for selection of biopsy GS 6 prostate cancer being at risk for up-grading at prostatectomy.
|
27191985 |
2016 |
Prostate carcinoma
|
0.030 |
Biomarker
|
disease |
BEFREE |
HELLS was independently predictive for biochemical-recurrence after radical prostatectomy (HR 2.3; CI 1.5-3.6; p < 0.01).In conclusion, HELLS and ZIC5 might be promising candidate markers for selection of biopsy GS 6 prostate cancer being at risk for up-grading at prostatectomy.
|
27191985 |
2016 |
Congenital Abnormality
|
0.030 |
GeneticVariation
|
group |
BEFREE |
The rare concurrence of these major brain malformations in our patients provides further evidence that 13q32.2q32.3 deletion, harboring ZIC2 and ZIC5, leads to cerebellar dysgenesis.
|
25454392 |
2015 |
Congenital Abnormality
|
0.030 |
GeneticVariation
|
group |
BEFREE |
The minimal deletion interval associated with the Dandy-Walker malformation (DWM) was narrowed to the 13q32.2-33.2 region, in which the ZIC2 and ZIC5 genes proposed as underlying various CNS malformations are mapped.
|
17209130 |
2007 |